Aegerion Pharmaceuticals, Inc. (AEGR)
-NasdaqGS 63.70 
1.36(2.18%) 4:00PM EDT|After Hours
:
62.10 1.60 (2.51%) 6:20PM EDT
| Prev Close: | 62.34 |
|---|
| Open: | 62.47 |
|---|
| Bid: | N/A |
|---|
| Ask: | 65.25 x 200 |
|---|
| 1y Target Est: | 83.10 |
|---|
| Beta: | 0.85 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 60.71 - 64.69 |
|---|
| 52wk Range: | 12.87 - 75.69 |
|---|
| Volume: | 934,286 |
|---|
| Avg Vol (3m): | 670,692 |
|---|
| Market Cap: | 1.84B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.71 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage decreasesAP(Tue 6:04PM EDT)
- The NIH Aims To Develop Drugs That Big Pharma Discardedat Forbes(Tue 12:16PM EDT)
- Isis Pharmaceuticals Making Antisenseat Seeking Alpha(Mon, Jun 17)
- Aegerion Pharmaceuticals Inc. (AEGR): Today's Featured Health Care Laggardat TheStreet(Thu, Jun 13)
- Analysts: Aegerion’s Lojuxta Shows Promise and 3 More Research Notes to Browseat Wall St. Cheat Sheet(Wed, Jun 12)
- Why Aegerion Is Worth 1,732 Times Salesat Seeking Alpha(Wed, Jun 12)
- This Week in Biotechat Motley Fool(Sat, Jun 8)
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement ProgramGlobeNewswire(Thu, Jun 6)
- [video] A Drug to Fight HoFHat CNBC(Wed, Jun 5)
- January 2015 Options Now Available For Aegerion Pharmaceuticalsat Forbes(Wed, Jun 5)
- CHMP Positive on Aegerion's LojuxtaZacks(Mon, Jun 3)
- Analysts: Coinstar Trends Could Kill Free Cash Flow and 3 More Research Notes to Browseat Wall St. Cheat Sheet(Mon, Jun 3)
- Aegerion Pharmaceuticals, Inc. - Special Callat Seeking Alpha(Mon, Jun 3)
- Aegerion And Other Top Small-Cap Biotech Buys By Mega Funds In March 2013 Quarterat Seeking Alpha(Mon, Jun 3)
- Europe is Positive on these 2 Drugsat Motley Fool(Sat, Jun 1)
Key Statistics
| Forward P/E (1 yr): | 106.17 |
|---|
| P/S (ttm): | 1,459.45 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.24 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.62 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | 0.48 |
|---|
Business Summary
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States.
View More